- Home
- AQB vs PBM Comparison
AQB vs PBM Comparison
Compare AQB & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- PBM
- Stock Information
- Founded
- AQB 1991
- PBM 1994
- Country
- AQB United States
- PBM Canada
- Employees
- AQB N/A
- PBM N/A
- Industry
- AQB
- PBM
- Sector
- AQB
- PBM
- Exchange
- AQB Nasdaq
- PBM NYSE
- Market Cap
- AQB 4.4M
- PBM 4.0M
- IPO Year
- AQB N/A
- PBM N/A
- Fundamental
- Price
- AQB $0.94
- PBM $0.04
- Analyst Decision
- AQB Hold
- PBM
- Analyst Count
- AQB 2
- PBM 0
- Target Price
- AQB N/A
- PBM N/A
- AVG Volume (30 Days)
- AQB 16.2K
- PBM 8.7M
- Earning Date
- AQB 11-05-2024
- PBM 11-29-2024
- Dividend Yield
- AQB N/A
- PBM N/A
- EPS Growth
- AQB N/A
- PBM N/A
- EPS
- AQB N/A
- PBM N/A
- Revenue
- AQB $1,258,512.00
- PBM N/A
- Revenue This Year
- AQB N/A
- PBM N/A
- Revenue Next Year
- AQB $57.86
- PBM N/A
- P/E Ratio
- AQB N/A
- PBM N/A
- Revenue Growth
- AQB N/A
- PBM N/A
- 52 Week Low
- AQB $0.82
- PBM $0.04
- 52 Week High
- AQB $4.03
- PBM $13.69
- Technical
- Relative Strength Index (RSI)
- AQB 31.41
- PBM 26.29
- Support Level
- AQB $0.96
- PBM $0.06
- Resistance Level
- AQB $1.05
- PBM $0.06
- Average True Range (ATR)
- AQB 0.04
- PBM 0.01
- MACD
- AQB -0.01
- PBM 0.00
- Stochastic Oscillator
- AQB 6.92
- PBM 1.57
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.